資料來源：https://www.bloomberg.com/news/articles/2016-06-29/drug-companies-need-to-tell-a-better-story-regeneron-ceo-says 

As U.S. politicians including presidential candidates Hillary Clinton and Donald Trump shower criticism on the pharmaceutical industry, drugmakers need to change their tune, Regeneron Pharmaceuticals Inc. Chief Executive Officer Len Schleifer said.

"We are going to have to do a better job at explaining the value proposition of products we bring out," Schleifer said Wednesday at a Bloomberg pharma event in New York. "We need to be reasonable about the way we price these things."

Over the last 12 months the Nasdaq Biotechnology Index had fallen 31 percent as of Tuesday’s close, battered in part by political pressure from both Democrats and Republicans. Regeneron’s stock dropped in line with the industry, down 33 percent over the period.

Regeneron has faced pushback on pricing from insurers and drug benefit managers, which have put up barriers such as heavy medical paperwork to slow patient access to its new drug to treat high cholesterol, Praluent. With those roadblocks in place the drug -- which has a list price of $14,600 for a year’s treatment, before discounts -- brought in only $13 million in sales in the first quarter.

"Pharma gets bad press because they do some bad things," Schleifer said. Practices like jacking up drug prices and promoting medicines beyond their regulatory category have both given the industry a bad name, he said. But high prices are necessary to promote drug development for critical conditions, the CEO said.

"There’s no one in the ICU that hates the pharma industry," he said, referring to the intensive care unit in hospitals. "They all want us to have a drug that will get them out of there."

The Nasdaq Biotechnology Index slumped further after the U.K.’s vote to exit the European Union rocked global markets, and while it recovered in the past two days, it’s still below its closing Thursday. In the U.K., however, pharmaceutical stocks have been seen as a relatively safe spot. The FTSE 350 Pharmaceuticals & Biotechnology Index rose 6.5 percent after the vote through Tuesday’s close, compared with a 3.1 percent decline in the broader FTSE 100 Index.

The U.K. voters’ decision to exit the European Union last week won’t pose a structural challenge to drugmakers, Schleifer said. Regeneron has tie-ups with large European drugmakers including Germany’s Bayer AG and France’s Sanofi, which owns a stake of about 23 percent in Regeneron and is a partner for drugs including Praluent.